Highlights Gan & Lee Pharmaceuticals.

Equities

603087

CNE100003ZH1

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-06-27 EDT			5-day change	1st Jan Change
46.32 ^CNY	-1.19%		-9.07%	-12.02%

06-17	Gan & Lee Pharmaceuticals.(SHSE:603087) added to SSE 180 Index	CI
06-17	Gan & Lee Pharmaceuticals.(SHSE:603087) added to Shanghai Stock Exchange 180 Value Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gan & Lee Pharmaceuticals Gets Mexico's Drug Registration Approval for Insulin Glargine Injection	05-24	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2023	04-24	CI
Gan & Lee Pharma's Insulin Product Gets Registration Approval in Bolivia	01-26	MT
Gan & Lee Pharmaceuticals Administers First Subject in Phase II Study of GZR101 Diabetes Drug	12-12	MT
Gan & Lee Pharmaceuticals' Unit Gets Nod to Test GZR18 Tablets	12-04	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1023 Injection	23-07-20	MT
Gan & Lee Pharmaceuticals Gets Regulatory Nod for Private Placement	23-06-20	MT
Pharmaktiv acquired remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals..	23-06-13	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Gan & Lee Pharmaceuticals' Insulin Injection Enters Pakistani Market	22-12-09	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Gan & Lee Pharma Co-Founder to Buy $111 Million More Shares; Shares Up Nearly 6%	22-10-25	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Gan & Lee Pharma Wins Nod to Market Diabetes Drug in Kazakhstan	22-08-25	MT
Gan & Lee Pharma Wins Nod From FDA to Trial Diabetes Drug	22-08-09	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gan & Lee Pharmaceuticals.

Equities

603087

CNE100003ZH1

Highlights

Filters